Targeting neuronal apoptosis after intracerebral hemorrhage (ICH) may be an important therapeutic strategy for ICH patients. Emerging evidence indicates that C1q/TNF-Related Protein 9 (CTRP9), a newly discovered adiponectin receptor agonist, exerts neuroprotection in cerebrovascular disease. The aim of this study was to investigate the anti-apoptotic role of CTRP9 after experimental ICH and to explore the underlying molecular mechanisms. ICH was induced in mice via intrastriatal injection of bacterial collagenase. Recombinant CTRP9 (rCTRP9) was administrated intranasally at 1 h after ICH. To elucidate the underlying mechanisms, adiponectin receptor1 small interfering ribonucleic acid (AdipoR1 siRNA) and selective PI3 K inhibitor LY294002 were administered prior to rCTRP9 treatment. Western blots, neurofunctional assessments, immunofluorescence staining, and Fluoro-Jade C (FJC) staining experiments were performed. Administration of rCTRP9 significantly improved both short-and long-term neurofunctional behavior after ICH. RCTRP9 treatment significantly increased the expression of AdipoR1, PI3 K, p-Akt, and Bcl-2, while at the same time was found to decrease the expression of Bax in the brain, which was reversed by inhibition of AdipoR1 and PI3 K. The neuroprotective effect of rCTRP9 after ICH was mediated by attenuation of neuronal apoptosis via the AdipoR1/PI3K/Akt signaling pathway; therefore, rCTRP9 should be further evaluated as a potential therapeutic agent for ICH patients.
Introduction
Intracerebral hemorrhage (ICH) is a stroke subtype with a high mortality and morbidity rate that accounts for 10-15% of all strokes worldwide [1] [2] [3] . Despite its devastating socioeconomic burden on individuals and society, ICH remains an unresolved medical problem with little improvement in patient outcomes over the past 20 years 4 . Regarding the pathophysiology of ICH, it is generally accepted that the intraparenchymal hematoma compressing the surrounding brain tissue is considered to elicit the primary brain injury; then red blood cell debris and other clot components lead to secondary brain injury (SBI), which involves a series of molecular processes including inflammatory responses, activation of apoptosis cascades, ischemia, blood-brain barrier disruption, and brain edema formation. Apoptosis is the main form of cell death within the brain region surrounding the intracerebral hematoma 5, 6 . Furthermore, it has been shown that the extent of neuronal apoptosis is closely related to impaired neurological functions 7, 8 . Therefore, inhibiting neuronal apoptosis after ICH may alleviate neurological deficits and improve overall patient outcomes.
Adiponectin (APN) is an adipose-derived secretory serum protein that has been shown to alter multiple functions in the peripheral and central nervous systems [9] [10] [11] . However, APN knock-out mice exhibit highly variable phenotypes 12 . Because APN has a C-terminal globular domain with sequence homology to the immune complement protein C1q, it belongs to the larger family of C1q proteins 13 . C1q/TNF-related proteins (CTRPs) have similar structural and biochemical properties as APN [14] [15] [16] . Of all identified CTRPs, CTRP9 shares the highest degree of sequence identity (54%) with APN at the presumed functional globular domain 15 . APN exerts its physiological effects by binding to and thereby activating its specific receptors. Currently two APN receptors, AdipoR1 and AdipoR2, have been identified. AdipoR1 is widely expressed in the central nervous system (CNS), especially on neurons 17 . It has been reported that AdipoR1 agonists participate in neuroprotective actions against ischemic stroke, particularly by reducing neuronal apoptosis 18 . Two recent studies suggest that the anti-apoptotic effects of AdipoR1 agonists are mediated via the phosphatidylinositol 3-kinase (PI3 K)/ protein kinase B (Akt) signaling pathway 19, 20 . It has been shown that CTRP9 exerts a high affinity to AdipoR1 21 , and emerging evidence suggests that CTRP9 has the potential to carry out neuroprotective functions on diverse CNS disease 22 . However, the anti-apoptotic effects of CTRP9 following ICH have not yet been illustrated.
The present study aimed to assess the effects of CTRP9 on neurofunctional outcomes and neuronal apoptosis in mice subjected to experimental ICH. The mechanisms of the observed effects were then explored using AdipoR1 siRNA and PI3 K inhibitor, LY294002.
Materials and Methods Animals
A total of 144 male CD1 mice (8 weeks old, weight 30-40 g; Charles River, Wilmington, MA, USA) were housed in a temperature and humidity-controlled room with a 12-hour light/dark cycle and free access to food and water. All animals were acclimated to the environment for a minimum of 3 days before being subjected to ICH induction or sham surgery. The experimental protocols and procedures for this study were approved by the Institutional Animal Care and Use Committee (IACUC) at Loma Linda University (IACUC No. 8160049) and were in compliance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals.
ICH Model and Study Design
Experimental ICH was induced in mice by intrastriatal injection of bacterial collagenase, as previously reported 23 .
Briefly, mice were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) (2:1, intraperitoneal injection) and positioned prone in a stereotaxic head frame (Kopf Instruments, Tujunga, CA, USA). A 1-mm cranial burr hole was drilled, and a 26-gauge needle on a 10-ml Hamilton syringe was inserted stereotactically into the right striatum (coordinates 0.2 mm posterior, 2.2 mm lateral to the bregma, and 3.5 mm below the dura). Bacterial collagenase type VII-S (0.075 units) (Sigma-Aldrich, St. Louis, MO, USA) dissolved in 0.5 ml sterile phosphate-buffered saline (PBS) was infused into the brain at a rate of 0.167 ml/min with an infusion pump (Stoelting, Harvard Apparatus, Holliston, MA, USA). The needle was left in place for an additional 5 min after the injection to prevent possible leakage of the collagenase solution before being withdrawn slowly at a rate of 1 mm/min. The cranial burr hole was sealed with bone wax, the scalp was sutured, and 0.4 ml of normal saline was injected subcutaneously to avoid postsurgical dehydration. Mice were allowed to recover fully under close observation. The sham operation was performed following the same protocol but involved needle insertion only. All mice were randomly assigned to the following four separate experiments as shown in the timeline of the experimental design (Additional file 1: Fig. S1 ). Experimental groups, animal numbers, and mortality rates of this current study are summarized in the supplemental material (Additional file 2: Table S1 ).
Experiment 1.
To determine the time course of endogenous AdipoR1 and CTRP9 expression in the brain of mice subjected to ICH, n¼36 mice were divided into six groups (n¼6/group) including sham as well as ICH after 3, 6, 12, 24, and 72 h. Two additional mice were used for double immunohistochemistry staining of AdipoR1 combined with specific markers for neurons, astrocytes, and microglia at 24 h after ICH. Experiment 2. To evaluate the short-term neurofunctional deficits and the extent of neuronal apoptosis, n¼27 mice were randomly divided into three groups (n¼9/group): sham, ICHþvehicle (PBS), ICHþrCTRP9 (0.1 mg/g). Recombinant CTRP9 (rCTRP9) was administered intranasally at 1 h post-ICH. Neurofunctional tests and Fluoro-Jade C (FJC) staining were conducted at 24 h post-ICH.
Experiment 3.
To assess long-term neurofunctional deficits, n¼24 mice were divided into three groups (n¼8/group): sham, ICHþvehicle (PBS), ICHþrCTRP9 (0.1 mg/g). The foot-fault test and rotarod test were performed on days 7, 14, and 21 post-ICH, and the Morris water maze test was conducted on days 21-25 post-ICH.
Experiment 4.
To verify the anti-apoptotic mechanism of rCTRP9, n¼42 mice were divided into seven groups (n¼6/ group): sham, ICHþvehicle (PBS), ICHþrCTRP9 (0.1 mg/g), ICHþrCTRP9þAdipoR1 siRNA, ICHþrCTRP9þScramble siRNA (Scr siRNA), ICHþrCTRP9þLY294002 (specific PI3 K inhibitor), ICHþrCTRP9þDMSO (5 ml of 5% dimethyl sulfoxide in PBS). LY294002 and DMSO were delivered intracerebroventricularly 30 min before ICH 24 and scrambled siRNA and AdipoR1 siRNA were injected intracerebroventricularly 48 h before ICH 25 . Neurofunctional testing and western blot were performed at 24 h post-ICH.
Western Blot Analysis
Western blot was performed as previously described 26 . Briefly, mice were transcardially perfused with ice-cold PBS under deep anesthesia, and brains were removed and separated into two hemispheres at 24 h after ICH induction or sham surgeries. The ipsilateral/right brain hemispheres were homogenized in RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and centrifuged at 4 C for 30 min at 14,000 g. The supernatant was collected, and the protein concentration was determined using a detergent compatible assay (DC protein assay, Bio-Rad Laboratories, CA, USA). Equal amounts of protein were loaded on an SDS-PAGE gel and run using electrophoresis and then transferred to a nitrocellulose membrane. 
Immunofluorescence Staining
The brain samples used for immunohistochemistry staining were prepared according to a previously described protocol 27 . Briefly, animals were deeply anesthetized at 24 h after ICH and transcardially perfused with 100 ml ice-cold PBS followed by 60 ml of 10% paraformaldehyde. The whole brain was collected and fixed in 10% paraformaldehyde for 24 h and dehydrated in a 30% sucrose solution for 3 days. After being kept frozen at -80 C, brains were cut into 8 mmthick coronal sections on a cryostat (LM3050 S; Leica Microsystems, Bannockburn, Germany). Immunofluorescence staining was conducted as previously described 28 . Briefly, brain samples were incubated overnight at 4 C with the primary antibodies including anti-Iba-1 (1:200, ab178847, Abcam), anti-NeuN (1:200, ab177487, Abcam) and anti-GFAP (1:200, ab16997, Abcam), and anti-AdipoR1 (1:200, ab126611, Abcam). The corresponding secondary antibodies (1:500, Jackson Immunoresearch, West Grove, PA, USA) were added to the brain sections and allowed to incubate at room temperature for 2 h. The sections were visualized and photographed by using a fluorescence microscope (Leica Microsystems).
Short-Term Neurofunctional Assessments
Short-term neurofunctional behavior was assessed with the modified Garcia score, forelimb placement test, and corner turn test involving an independent researcher blinded to the experimental groups. All tests were performed at 24 h after ICH induction or sham surgery, as previously described 29, 30 . The Garcia score includes seven individual tests that evaluate spontaneous activity, vibrissae proprioception, axial sensation, symmetry of limb movement, lateral turning, forelimb walking, and climbing. Each subtest was given a score ranging from 0 to 3, with a composite maximum score of 21 (no neurological deficits). The forelimb placement test was used to assess the animals' responsiveness to vibrissae stimulation, and results were expressed as a percentage of the number of successful left forepaw placements out of 10 stimulations, normalized to the mean of sham performance. For the corner turn test, animals were allowed to advance into a 30 corner and exit by turning either to the left or right. Choice of turning was recorded for a total of 10 trials, and a score was calculated as number of left turns/all trials Â 100.
Fluoro-Jade C Staining
Degenerating neurons were evaluated by FJC staining as previously described utilizing a modified FJC ready-todilute staining kit (Biosensis, USA) according to the manufacturer's instructions 31, 32 . Briefly, FJC-positive neurons were counted in six sections per brain at Â200 magnification by an independent observer. Quantified analysis was performed with Image J software (Image J 1.4, NIH, Bethesda, MD, USA). The data were presented as the average number of FJC-positive neurons in the fields (cells/mm 2 ).
Drug Administration
Recombinant CTRP9 (rCTRP9) (cat# H00338872-P01, Novus Biologicals) dissolved in PBS was administered intranasally at 1 h post-ICH as previously reported 27 . A total volume of 20 ml of rCTRP9 solution was administered intranasally. Mice under anesthesia were placed in a supine position and rCTRP9 solution was administered in drops (5 ml/ drop) every 2 min, alternating between the left and right nares, over a period of approximately 20 min. The ICHþvehicle group was given an equal volume of PBS intranasally. The method for drug administration was the same for short-and long-term experiments.
Long-Term Neurofunctional Assessments
To evaluate the long-term neurofunctional outcomes after ICH, the foot-fault and rotarod tests were performed within the first, second, and third week post-ICH as previously described 33 . These tests specifically evaluate the rodents' sensorimotor function, coordination, and balance. Water maze tests were performed on days 21 to 25 post-ICH to evaluate memory and spatial learning as previously described 34 .
Intracerebroventricular Injection
Intracerebroventricular administration was performed as previously described 35 . AdipoR1 siRNA (cat# 4390771) and Scramble siRNA (scr siRNA) (cat# 4390843, Life Technologies, Carlsbad, CA, USA) were prepared at 500 pmol in RNAsefree suspension buffer and were infused (5 ml of the siRNAs) 48 h before ICH modeling in ICHþrCTRP9þAdipoR1 siRNA and ICHþrCTRP9þScr siRNA mice, respectively. LY294002 (Selleck Chemicals, Houston, TX, USA) was prepared at 50 mmol/l in PBS (contains 25% DMSO), and 5 ml of the DMSO and LY294002 were infused 30 min before ICH induction in ICHþrCTRP9þLY294002 and ICHþrCTRP9þDMSO mice, respectively. The 26-gauge needle of a 10-ml Hamilton syringe was inserted into the left lateral ventricle through a cranial burr hole at the following coordinates relative to bregma: 0.3 mm posterior, 1.0 mm lateral, and 2.3 mm below the dura. A microinfusion pump was used for the intracerebroventricular administrations at a rate of 0.667 ml/min. The needle was left in place for an additional 5 min after the end of infusion before being slowly withdrawn over 3 min. The burr hole was sealed with bone wax.
Statistical Analysis
All data were expressed as the mean and standard deviation (mean + SD). Statistical analysis was performed with Graph Pad Prism (Graph Pad Software Inc., San Diego, CA, USA). Data were analyzed by one-way analysis of variance (ANOVA) followed by multiple comparisons between groups using Tukey's post-hoc test. A P-value of less than 0.05 was considered statistically significant.
Results

Animal Mortality and Exclusion
None of the sham animals died prior to euthanasia. The total animal mortality rate in this study was 11.3% (13/115). The mortality rate was not significantly different between the experimental groups (Additional file 2: Table S1 ).
The Endogenous Expressions Time Course of AdipoR1 and CTRP9 after ICH
Western blot was performed to assess the protein expression of AdipoR1 and CTRP9 in the ipsilateral/right cerebral hemispheres of sham animals or at 3, 6, 12, 24, and 72 h after ICH induction. The endogenous expressions of AdipoR1 and CTRP9 continuously increased after surgery, reached a peak at 24 h, and then decreased again at 72 h after ICH induction (p<0.05 compared with sham, Fig. 1A , B). Double immunofluorescence staining was performed to detect the localization of AdipoR1 on neurons (NeuN), microglia/macrophages (Iba-1), and astrocytes (GFAP) at 24 h after ICH. AdipoR1 was mainly expressed on neurons and astrocytes after ICH (Fig. 1C). rCTRP9 Ameliorated Short-Term Neurofunctional Deficits after ICH ICH induction significantly reduced the composite modified Garcia score, as well as performances of the forelimb placement and corner turn test at 24 h after surgery when compared with sham animals. The neurofunctional impairments were significantly ameliorated by administration of rCTRP9 (0.1 mg/g) as seen in the ICHþrCTRP9 group, (p<0.05 compared with the vehicle group, Fig. 2A-C) .
rCTRP9 Attenuated Neuronal Apoptosis after ICH
FJC was used to evaluate the severity of neuronal degeneration and apoptosis in the ipsilateral hemisphere at 24 h after ICH (Fig. 3B) . ICH induction resulted in a significantly increased number of FJC-positive cells (ICHþvehicle) when compared with sham animals (p<0.05); however, rCTRP9 treatment (0.1 mg/g) significantly reduced the number of apoptotic cells as demonstrated in the ICHþrCTRP9 group (p<0.05 compared with ICHþvehicle, Fig. 3A and C).
rCTRP9 Improved Long-Term Neurofunctional Outcomes after ICH
At the first, second, and third week after surgery, mice randomized to the ICHþvehicle group demonstrated significantly more foot faults of the left forelimb as well as shorter falling latencies than those animals randomized to the sham group (p<0.05, Fig. 4A, B) . However, animals in the ICHþrCTRP9 group demonstrated significantly fewer missteps with the left forelimb as well as longer walking periods on the rotarod before falling when compared with the vehicle group (p<0.05, Fig. 4A, B) .
During Morris water maze testing, the swim distance and escape latency measured for vehicle animals to find a platform within a pool of water were found significantly increased when compared with the sham group (p<0.05, Fig.  4C, D) . However, a significantly shorter swim distance and escape latency was observed in the ICHþrCTRP9 group on days 3 to 5 of testing (p<0.05 compared with ICHþvehicle, Fig. 4C, D) .
AdipoR1 siRNA and PI3 K Inhibitor Reversed the Neurofunctional Improvements Seen with rCTRP9 Therapy
Administration of rCTRP9 resulted in improved neurofunctional performances after ICH, which was assessed via neurofunctional tests including the modified Garcia test, forelimb placement test, and corner turn test at 24 h after ICH. The neurofunctional improvements seen with rCTRP9 therapy were reversed by administration of AdipoR1 siRNA and specific PI3 K inhibitor LY294002 (p<0.05 compared with ICHþrCTRP9, Fig. 5A-C) . after surgery (p<0.05, Fig. 6A, B) . Moreover, the expressions of phosphorylated Akt, Bcl-2 were significantly increased, while the expression of Bax was significantly decreased in the ICHþrCTRP9 group when compared with the ICHþvehicle group at 24 h after surgery (p<0.05, Fig.  6A, B) . However, inhibition of AdipoR1 with AdipoR1 siRNA significantly decreased the expression of AdipoR1, PI3 K, phosphorylated Akt and Bcl-2, and increased the expression of Bax when compared with the ICHþrCTRP9þ scr siRNA group at 24 h after ICH (p<0.05, Fig. 6B ). Similarly, pretreatment with LY294002 significantly decreased the expression of PI3 K and the expression of the downstream molecules p-Akt, as well as Bcl-2 and increased the expression of Bax in the ICHþrCTRP9þLY294002 group when compared with the ICHþrCTRP9þDMSO group at 24 h after ICH (p<0.05, Fig. 6B ).
Discussion
In this present study, we first investigated the potential antiapoptosis effect of rCTRP9 and explored the possible underlying mechanism of rCTRP9 after ICH. We discovered that the expression of AdipoR1 and rCTRP9 increased after ICH induction. AdipoR1 was found to be expressed in neurons, astrocytes, and microglia cells. Administration of rCTRP9 attenuated neuronal apoptosis and preserved neurological function after ICH. Administration of rCTRP9 was associated with upregulation of AdipoR1, PI3 K, p-Akt, and Bcl-2, and downregulation of Bax after ICH. However, blockage of AdipoR1 and PI3 K reversed the beneficial effects of rCTRP9 on neurofunctional deficits and neuronal apoptosis. Conclusively, our findings suggest that administration of rCTRP9 might attenuate neuronal apoptosis after ICH, which was, at least in part, mediated by the AdipoR1/ PI3K/Akt signaling pathway.
The APN receptor is an emerging potential target in diverse CNS disease [36] [37] [38] . Activation of APN receptors results in adequate regulation of cellular metabolism, and exerts anti-atherosclerosis and anti-inflammatory effects [39] [40] [41] . Although APN receptors have been shown to exist abundantly in the brain, their exact role in brain diseases remains unclear. Two APN receptors have been identified: AdipoR1 and AdipoR2. Recent studies reported that AdipoR1 and AdipoR2 are both expressed within cortical neurons of mice, with AdipoR1 being more pronounced than AdipoR2 42 . Furthermore, AdipoR1 binds to globular APN with higher affinity than AdipoR2. AdipoR2 has an intermediate binding affinity for both globular APN and full-length APN 17 . Previous studies revealed that AdipoR1 was widely expressed in neurons, astrocytes, and microglial cells 43 . Furthermore, our results indicate that the expression of AdipoR1 increases within 24 h following ICH. Based on our immunohistochemistry data, the expression of AdipoR1 was observed in neurons, astrocytes, and microglia, which is consistent with the results of the aforementioned studies. The increase in AdipoR1 expression within the ipsilateral brain hemisphere after ICH inductions requires further explanation; however, we suggest that the observed change in AdipoR1 expression might be a response to the stress reaction induced by ICH. Moreover, the expression of AdipoR1 was further elevated after administration of rCTRP9. The effects of rCTRP9 on AdipoR1 expression were consistent with the results of a previous study, which showed that APN increased the expression of AdipoR1 and protected the brain tissue against the detrimental effects of ischemic stroke 44 . APN is an adipokine that is predominantly secreted by adipocytes. It has numerous functions, including regulation of metabolism, anti-inflammation, protection against endothelial dysfunction, and protection against ischemic injury 40, 41 . The CTRPs are a newly discovered, highly conserved family of APN paralogs, containing 15 members (CTRP1 to CTRP15). This specific protein family exhibits similar structure as APN, consisting of four distinct domains including a N-terminal signal peptide, a short variable domain, a collagen-like domain, and a C-terminal C1q-like globular domain 45, 46 . Of all CTRP paralogs, CTRP9 shows the highest degree of amino acid identity to APN in its globular C1q domain. In the present study, we demonstrated for the first time that CTRP9 has anti-apoptotic effects protecting neurons from ICH-induced SBI. Furthermore, we evaluated the temporal expression of endogenous CTRP9 within 72 h after experimental ICH. The results indicated that CTRP9 expression increased after ICH and reached the highest level at 24 h from ICH induction.
It is generally believed that neuronal apoptosis is a crucial process leading to secondary neurological damage after ICH 47, 48 . The anti-apoptotic effects of AdipoR1 have been reported in an obese model 44 . It has been reported that APN receptor activation attenuates human hepatocytes, HepG2 cells apoptosis via the PI3K/Akt pathway 49 . Two recent studies suggest that the anti-apoptotic effects of AdipoR1 agonists are mediated via PI3K/Akt signaling pathway 50 . Although anti-apoptotic effects of APN have been previously reported in many disease models [51] [52] [53] , the underlying mechanism remains unclear. PI3 K is a protein tyrosine kinase activated by a cytokine receptor. Activated PI3 K activates cytoplasmic Akt via phosphorylation, thereby regulating expression of genes involved in cell survival, proliferation, cell-cycle progression, and angiogenesis in cerebral development and disorders 54, 55 . It has been reported that activated PI3K/Akt signaling improves neurological function and attenuates neuronal apoptosis in murine models of subarachnoid hemorrhage (SAH) 34 . The present study showed that CTRP9 treatment attenuated neuronal apoptosis following ICH. Specifically, CTRP9 treatment upregulated the expression of the targeted proteins on the pathway (AdipoR1, PI3 K, and p-Akt) as well as the anti-apoptotic molecular marker (Bcl-2) and downregulated the expression of the pro-apoptotic molecular marker (Bax). When AdipoR1 was silenced by AdipoR1 siRNA pretreatment, expression of AdipoR1, PI3 K, p-Akt, Bcl-2 was suppressed and expression of Bax was enhanced, suggesting that anti-apoptotic effects of CTRP9 were abolished. Similarly, pretreatment with a PI3 K inhibitor blocked the activation of PI3 K and p-Akt by rCTRP9, leading to decreased expression of antiapoptotic marker (Bcl-2) and increased expression of pro-apoptotic marker (Bax). These findings suggest that activation of PI3K/Akt signaling pathway underlies the antiapoptotic effects of CTRP9.
There were some limitations in our study. First, the present study did not rule out the possible neuroprotective effects of CTRP9 through preservation of the blood-brain barrier or alleviation of neuroinflammation. Therefore, further studies must be conducted to explore the aforementioned possibilities. Second, the pathophysiology of neuronal apoptosis after ICH is a complex network. Other downstream factors such as mitogen-activated protein kinase (MAPK), adenosine monophosphate-activated protein kinase (AMPK) may be modulated by rCTRP9 administration after ICH, which was not explored in this study. Another limitation is that we have evaluated the total expression of PI3 K rather than its activated phosphorylated form.
In the current study, we focused on AdipoR1/PI3K/Akt signaling in regards to anti-apoptotic molecular mechanisms. Further studies need to be conducted to explore other potential signaling pathways contributed by rCTRP9 and AdipoR1 activation. Third, in our experiments, we used adult CD1 mice to mimic the progression of ICH; however, ICH tends to occur in older patients with hypertension, vascular disorders, and cerebral amyloid angiopathy 56 . We did not evaluate the effects of rCTRP9 in different age groups or in animals with systemic co-morbidities.
Conclusions
In summary, we showed for the first time that rCTRP9 administration improved neurological function and reduced neuronal apoptosis through AdipoR1/PI3K/Akt pathway in an experimental ICH model. Therefore, administration of rCTRP9 may be a promising therapeutic strategy in ICH management. Further studies need to evaluate further mechanisms and applications of rCTRP9 in the CNS.
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